What CGM Data Reveals About Long-Term Diabetes Complications

For years, HbA1c has been the primary measure doctors use to assess diabetes control and predict future complications. But continuous glucose monitoring (CGM) has changed the game by showing what's actually happening with your blood sugar throughout the day. Researchers wanted to know whether the detailed picture CGM provides—beyond HbA1c alone—could help predict which people are at risk for long-term complications like kidney disease, vision loss, and nerve damage.

This five-year study followed 246 adults with type 1 diabetes at a tertiary referral center, tracking not just their HbA1c but also detailed CGM metrics. The goal was to understand whether CGM patterns could actually forecast who would develop microvascular complications down the road.

Over the five years, the study group improved overall: average HbA1c dropped from 7.6% to 7.2%, and time in range increased from 50% to 61%. These are meaningful improvements in glucose control.

But the most striking finding was about what happened to individual people's time in range. Those whose TIR worsened by 10 percentage points or more had a 33.3% rate of developing microvascular complications. By contrast, people who maintained stable TIR had a 7.9% complication rate, while those who improved TIR by 10% or more saw a 15% rate. The difference between declining and stable TIR was particularly dramatic.

All CGM-derived metrics studied—including time in range, mean glucose, and glucose management indicator—showed associations with the composite endpoint of kidney, eye, and nerve complications.

If you use CGM, this study suggests that tracking trends in your time in range over time may be just as important as any single reading or your HbA1c number. A worsening pattern in your TIR could be an early signal to discuss with your healthcare team, even if your overall HbA1c hasn't moved much.

This doesn't mean perfect glucose control is required to avoid complications—the people with improving TIR and the people with stable TIR both had substantially lower complication rates than those whose TIR declined. Small, consistent improvements or maintaining your current level of control appears protective.

The findings provide real-world evidence that CGM metrics can help predict long-term risk, giving you and your care team more tools to make informed decisions about management strategies.

This was an observational study, meaning researchers tracked what happened naturally rather than testing an intervention. The participants came from a single tertiary referral center, so they may not fully represent all people with type 1 diabetes—for example, they may have had better access to technology and specialist care than the general population.

The study documents associations between worsening TIR and complications, but association is not the same as causation. Still, the five-year follow-up period and real-world design make this an important contribution to understanding how CGM patterns relate to long-term outcomes.

Source: The Journal of clinical endocrinology and metabolism. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.